Life sciences-focused Rosetta Capital has led a CHF 60m ($66m) series-B funding round for Swiss biotech Novimmune.
Deal is Recover's 23rd acquisition since it was established six years ago, and the third since being acquired by EQT
Gimv formed the climate control business in 2016 by merging Itho Daalderop and Klimaatgarant
Corporate venture arm Shell Ventures leads the round for the IoT energy systems software platform
GP invests in the company via Wisequity V, which closed on its €260m hard-cap in July 2019